These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

897 related items for PubMed ID: 32950042

  • 1. Postremission therapy with repeated courses of high-dose cytarabine, idarubicin, and limited autologous stem cell support achieves a very good long-term outcome in European leukemia net favorable and intermediate-risk acute myeloid leukemia.
    Borlenghi E, Cattaneo C, Cerqui E, Archetti S, Bertoli D, Bellotti D, Gramegna D, Soverini G, Oberti M, Schieppati F, Pagani C, Passi A, Sciumé M, Farina M, Carbone C, Crippa C, Dalceggio D, Tucci A, Rossi G.
    Hematol Oncol; 2020 Dec; 38(5):754-762. PubMed ID: 32950042
    [Abstract] [Full Text] [Related]

  • 2. Multicenter randomized phase II trial of idarubicin vs mitoxantrone, combined with VP-16 and cytarabine for induction/consolidation therapy, followed by a feasibility study of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia.
    Archimbaud E, Jehn U, Thomas X, De Cataldo F, Fillet G, Belhabri A, Peaud PY, Martin C, Amadori S, Willemze R.
    Leukemia; 1999 Jun; 13(6):843-9. PubMed ID: 10360370
    [Abstract] [Full Text] [Related]

  • 3. Results of program acute myeloid leukemia therapy use in National Medical Research Center for Hematology of the Ministry of Health of Russian Federation.
    Parovichnikova EN, Loukianova IA, Troitskaya VV, Drokov MY, Lobaova TI, Kuzmina LA, Sokolov AN, Kokhno AV, Fidarova ZT, Baskhaeva GA, Gavrilina OA, Vasilyeva VA, Obukhova TN, Kuznetsova SA, Sudarikov AB, Dvirnik VN, Galtseva IV, Davidiva JO, Kulikov SM, Savchenko VG.
    Ter Arkh; 2018 Aug 17; 90(7):14-22. PubMed ID: 30701918
    [Abstract] [Full Text] [Related]

  • 4. [Treating patients with acute myeloid leukemias (AML) according to the protocol of the AML-01.10 Russian multicenter randomized trial: the coordinating center's results].
    Parovichnikova EN, Troitskaia VV, Kliasova GA, Kuz'mina LA, Sokolov AN, Paramonova EV, Galstian GM, Kessel'man SA, Drokov MIu, Vasil'eva VA, Obukhova TN, Kulikov SM, Savchenko VG.
    Ter Arkh; 2014 Aug 17; 86(7):14-23. PubMed ID: 25314773
    [Abstract] [Full Text] [Related]

  • 5. Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61-70 years: results of the prospective EORTC-GIMEMA AML-13 study.
    Thomas X, Suciu S, Rio B, Leone G, Broccia G, Fillet G, Jehn U, Feremans W, Meloni G, Vignetti M, de Witte T, Amadori S.
    Haematologica; 2007 Mar 17; 92(3):389-96. PubMed ID: 17339189
    [Abstract] [Full Text] [Related]

  • 6. The efficacy and safety of daunorubicin versus idarubicin combined with cytarabine for induction therapy in acute myeloid leukemia: A meta-analysis of randomized clinical trials.
    Wang H, Xiao X, Xiao Q, Lu Y, Wu Y.
    Medicine (Baltimore); 2020 Jun 12; 99(24):e20094. PubMed ID: 32541448
    [Abstract] [Full Text] [Related]

  • 7. Fractionated doses of gemtuzumab ozogamicin combined with 3 + 7 induction chemotherapy as salvage treatment for young patients with acute myeloid leukemia in first relapse.
    Malfuson JV, Konopacki J, Thepenier C, Eddou H, Foissaud V, de Revel T.
    Ann Hematol; 2012 Dec 12; 91(12):1871-7. PubMed ID: 22820971
    [Abstract] [Full Text] [Related]

  • 8. [Long-term outcomes of homoharringtonine, cytarabine, daunorubicin or idarubicin (HAD/HAI) as induction chemotherapy in de novo acute myeloid leukemia].
    Qin T, Xu Z, Zhang Y, Lin Y, Ru K, Fang L, Zhang H, Pan L, Hu N, Qu S, Wang J, Xing R, Xiao Z.
    Zhonghua Xue Ye Xue Za Zhi; 2016 Feb 12; 37(2):94-9. PubMed ID: 27014976
    [Abstract] [Full Text] [Related]

  • 9. Transplantation of autologous peripheral blood progenitor cells procured after high-dose cytarabine-based consolidation chemotherapy for adults with secondary acute myelogenous leukemia in first remission.
    Schiller G, Lee M, Paquette R, Sawyers C, Khoubian F, Territo M.
    Leuk Lymphoma; 1999 May 12; 33(5-6):475-84. PubMed ID: 10342575
    [Abstract] [Full Text] [Related]

  • 10. [Outcomes of adult patients with de novo acute myeloid leukemia received idarubicin plus cytarabine regimen as induction chemotherapy].
    Ren X, Zhao T, Wang J, Zhu HH, Jiang H, Jia JS, Yang SM, Jiang B, Wang DB, Huang XJ, Jiang Q.
    Zhonghua Xue Ye Xue Za Zhi; 2018 Jan 14; 39(1):15-21. PubMed ID: 29551027
    [Abstract] [Full Text] [Related]

  • 11. Post-remission therapy of adults aged 60 and older with acute myeloid leukemia in first complete remission: role of treatment intensity on the outcome.
    Bouchacourt B, Hospital MA, Zemmour C, Rey J, d'Incan E, Charbonnier A, Mohty B, Saillard C, Bonnet S, Collignon A, Gelsi-Boyer V, Mozziconacci MJ, Blaise D, Vey N.
    Ann Hematol; 2020 Apr 14; 99(4):773-780. PubMed ID: 32088745
    [Abstract] [Full Text] [Related]

  • 12. Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study.
    Ravandi F, Assi R, Daver N, Benton CB, Kadia T, Thompson PA, Borthakur G, Alvarado Y, Jabbour EJ, Konopleva M, Takahashi K, Kornblau S, DiNardo CD, Estrov Z, Flores W, Basu S, Allison J, Sharma P, Pierce S, Pike A, Cortes JE, Garcia-Manero G, Kantarjian HM.
    Lancet Haematol; 2019 Sep 14; 6(9):e480-e488. PubMed ID: 31400961
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 45.